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a  b  s  t  r  a  c  t
Objectives:  To  compare  humoral  and  cellular  immune  responses  to tetanus  booster  vaccination  in infants
born  prematurely  with  those  born  at full  term  and  identify  factors  associated  with  the humoral  response.
Methods:  A  prospective  study  was  carried  out  on children  born  prematurely  and  with  a  birth  weight
<1500  g  and  with  infants  born  at full  term.  At  15  months  (pre-vaccination)  and  18 months  (post-
vaccination),  anti-tetanus  antibodies  were  measured  by ELISA;  the  intracellular  interferon-gamma
percentages  of  CD4+  T  and  CD8+  T cells  after  in vitro  stimulation  with  tetanus  toxoid  were  determined  by
ﬂow  cytometry.  Chi-squared  or Fisher’s  exact  test  was  used  to compare  categorical  variables.  Student’s
t-test  or  Mann–Whitney  test  was  used  to  compare  numerical  variables.  Regression  analysis  was per-
formed  to determine  factors  associated  with  humoral  immunity.  Statistical  signiﬁcance  was  considered
if  p <  0.05.
Results: Sixty-four  premature  and  54  full-term  infants  were  studied.  The  proportion  of children  immune
against  tetanus  at 15  and  18 months  was  similar  in both  groups.  The  geometric  mean  of  the  antibodies
was  lower  among  the  premature  children  at 15  months  (p =  0.025)  and  was  similar  in  both  groups  at
18  months  (p  = 0.852).  The  percentages  of CD4+  and  CD8+  T cells  expressing  intracellular  IFN- were
similar  in  both  groups  at 15  and  18  months.  Gestational  age  <32 weeks  was  associated  with  a reduction
of  −0.116  IU/mL  in  the  level  of  antibodies  at 15  months.  Breastfeeding  >6  months  was  associated  with  a
3.5-fold  greater  chance  of  optimal  protective  (≥0.1  IU/mL)  antibody  level  against  tetanus  at  15 months
and  an  increase  of 0.956  IU/mL  in the  level  of  antibodies  at 18  months.
Conclusions:  Humoral  and  cellular  response  following  a  tetanus  booster  was similar  in  both  groups.  Pre-
mature  infants  exhibited  lower levels  of  anti-tetanus  antibodies  at 15  months  of  age,  with  the lowest
levels  in  those  born  at a  gestational  age  of less  than  32  weeks.  Breastfeeding  was  associated  with  greater
levels  of antibody  against  tetanus.. Background
Studies suggest that even patients vaccinated against tetanus
nd with antibody levels considered protective may  acquire
etanus, depending on the immune status of the host and amount of
etanus neurotoxin produced by Clostridium tetani [1,2]. Moreover,
hildren born prior to a gestational age of 37 weeks may  exhibit a
ower immune response to vaccination and/or have an accelerated
ecay of serum antibodies [3–5].
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Factors that contribute to the survival of premature infants, such
as the use of prenatal steroids in women  at high risk of giving
premature birth [6] and the use of postnatal corticosteroids for
the treatment of bronchopulmonary dysplasia [7], may  also affect
the immune response to vaccination in children born prematurely
[5,8]. According to Slack et al. [5], the production of anti-tetanus
antibodies in premature infants with a gestational age of less than
32 weeks is negatively associated with the number of doses of
prenatal corticosteroids. Robinson et al. [8] found that antibody
levels following vaccination for tetanus, diphtheria and whooping
cough were lower in children with bronchopulmonary dysplasia
Open access under the Elsevier OA license.treated with dexamethasone. Moreover, breastfeeding, less preva-
lent among premature infants, and nutritional status, which may be
compromised in this population, are also involved in the immune
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It is not known whether the compromised immune response to
accination in premature infants is only related to vaccines admin-
stered in the ﬁrst six months of life. However, Kirmani et al. [3]
eported lower antibody levels following vaccination for diphthe-
ia, tetanus toxoid, poliovirus, Haemophilus inﬂuenzae type b and
epatitis B in seven-year-old children born at a gestational age of
ess than 29 weeks and with a birth weight of less than 1000 g in
omparison to children of the same age born at full term.
The  aims of the present study were to compare the humoral and
ellular immune response to a tetanus booster vaccine at 15 months
f age in infants born prematurely with those born at full term
nd to identify factors associated with humoral immune response.
peciﬁcally with regard to immune response, the concentration
f anti-tetanus antibodies and percentages of CD4+ T and CD8+ T
ells expressing intracellular interferon-gamma after in vitro stim-
lation with tetanus toxoid were compared before and after the
etanus booster vaccination.
.  Methods
The present prospective study was carried out between
eptember 2007 and January 2010 and received approval from the
thics Committee of the institution. All parents/guardians of the
articipants signed a statement of informed consent.
The inclusion criteria were children aged 15 months, having
eceived three doses of tetanus vaccine (at 2, 4 and 6 months of
ge) and not having yet received the tetanus booster vaccine. Partic-
pants were divided into two groups. The premature group included
hildren born with a gestational age of less than 37 weeks and
irth weight of less than 1500 g (very low birth weight preterm
nfants). These infants were assisted at the neonatal intensive care
nit of the Federal University of São Paulo, SP, Brazil, where preterm
nfants with birth weight less than 1500 g were followed up at
he multidisciplinary premature outpatient clinic of the institu-
ion. After delivery from the neonatal unit, these infants were
outinely followed up by pediatricians, neurologists, physiother-
pists, ophthalmologists, nutritionists, psychologists and dentists
ntil 20 years of age.
The  control group included children born at full term, adequate
or gestational age, with no neonatal complications, discharged
rom the maternity unit at two to four days of life and in follow
p at a pediatric outpatient clinic.
The exclusion criteria were: congenital malformation, chil-
ren of HIV-infected mothers, primary immunodeﬁciency, children
ho received plasma or immunoglobulin transfusions ﬁve months
efore or three weeks after the booster dose or received the tetanus
ooster vaccination prior to being invited to participate in the
tudy.
Infants included in the study were vaccinated according to the
razilian immunization recommendations. Brieﬂy, the routine vac-
ine schedule in Brazil is: BCG at birth; Hepatitis B at birth, 1, 2 and
 months of age (the 1-month dose, only for children born with
ess than 2 kg); tetanus and diphtheria toxoids and pertussis (DTP)
t 2, 4, 6 months and 4–6 years; H. inﬂuenzae type b (Hib) at 2,
 and 6 months; oral poliovirus at 2, 4, 6 months and 4–6 years;
otavirus at 2 and 4 months; 10-valent pneumococcal conjugate
accine at 3, 5, 7, 15 months; meningococcal C conjugate vaccine
Men C) at 3, 5, and 12 months; yellow fever vaccine at 9 months;
easles–mumps–rubella vaccine at 12 months and 4–6 years of
ge.
Maternal demographic and clinical characteristics as well ashildren’s data related to the period of hospitalization in the neona-
al unit and clinical complications in the ﬁrst year of life were
ollected. Gestational age was determined either by the best obstet-
ic estimate or using the New Ballard method [11]. The adjustment 30 (2012) 6521– 6526
of  birth weight to gestational age was  performed using the curve
proposed by Alexander et al. [12]. Clinical severity score in the
ﬁrst 12 h of life was  determined using the Score for Neonatal Acute
Physiology, Perinatal Extension, Version II (SNAPPE II) [13]. Nutri-
tional status at the time of vaccination was determined based on
the recommendations of the World Health Organization [14].
Four  mililiters of blood was  collected for the determination of
humoral and cellular immunity against tetanus toxoid at 15 months
of age (prior to the booster vaccine dose against tetanus, diphtheria
and whooping cough) and at 18 months of age (post-vaccination).
Double-antigen enzyme-linked immunosorbent assay (ELISA)
was used to determine humoral immunity, as described by Kris-
tiansen et al. [15]. The results were expressed in international
units per milliliter (IU/mL) by comparisons of the curves of the
plasma samples tested and the international reference standard.
Concentrations of anti-tetanus antibodies equal to or greater
than 0.1 IU/mL were considered optimal protective levels against
tetanus, concentrations between 0.01 and 0.1 IU/mL were con-
sidered minimal protective levels and concentrations lower than
0.01 IU/mL, susceptibility to the disease [1,16].
Cellular  immune response against tetanus toxoid was  deter-
mined by the percentages of CD4+ T and CD8+ T cells expressing
intracellular interferon-gamma after in vitro stimulation with
tetanus toxoid by ﬂow cytometry. A culture was done using full
blood diluted to 1:10 in RPMI 1640 culture medium (Gibco, NY,
USA) supplemented with l-glutamine, penicillin and streptomycin.
The diluted blood was then distributed in polystyrene tubes in
volumes of 1 mL.  Following the addition of the antigen, the tubes
were sealed and incubated at 37 ◦C for 72 h in an atmosphere with
5% CO2. For all tests, one tube of blood stimulated with phyto-
hemagglutinin was  used as the positive control and another of
non-stimulated blood was used as the negative control. Tetanus
toxoid was  obtained from Butantã Institute (São Paulo, Brazil).
In the last 4 h of incubation, brefeldin A was added at a concen-
tration of 10 g/mL to all tubes (Sigma, St. Louis, USA). CD3-APC
and CD8-PerCP conjugated monoclonal antibodies (BD Biosciences)
were used for cell-surface staining. Cells were ﬁxed, washed, resus-
pended with permeabilization buffer, and incubated for 10 min  in
the dark at room temperature. IFN-FITC-conjugated monoclonal
antibody was  then added. Finally, the cells were washed and kept
at +4 ◦C in the dark until data acquisition. Sample acquisition was
performed with FACSCalibur Cytometer (BD Biosciences) using Cell
Quest software (BD Biosciences). The analysis was  performed using
FlowJo software (Tree Star, Ashland, USA). Fifty thousand events
were acquired in the lymphocyte gate based on the forward scat-
ter and side scatter dot plot. CD3+ T cells were selected based on
the side scatter proﬁle and CD3-APC ﬂuorescence. CD8+ T lympho-
cytes were deﬁned as CD3+/CD8+; due to down regulation of CD4
molecules during activation, CD4+ T lymphocytes were deﬁned
as CD3+/CD8−. Intracellular IFN- production was evaluated in
CD3+/CD8+ and CD3+/CD8− cells. The ﬁnal value of positive cells to
each stimulus was obtained by subtracting the percentage of pos-
itive cells of the culture without stimulus (negative control) from
the culture in the presence of stimulus.
2.1. Statistical analysis
The  numerical variables were compared using either the Stu-
dent’s t-test (normal distribution) or the Mann–Whitney test
(non-normal distribution). The categorical variables were com-
pared using either the chi-squared (2) test or Fisher’s exact test.
Multiple linear regression analysis was  performed to determine
factors associated with tetanus antibody levels measured at 18
months. Variables associated with optimal protective antibody
level (≥0.1 IU/mL) against tetanus at 15 months of age were stud-
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as carried out using the Statistical Package for Social Sciences for
indows, version 17.0 (SPSS, Chicago, IL, USA), with the level of
igniﬁcance set to 5% (p < 0.05).
.  Results
Among the 89 premature infants in follow up at the prema-
ure outpatient clinic of the institution during the study period,
0 fulﬁlled the exclusion criteria. Sixty-nine premature infants and
0 full-term infants fulﬁlled the inclusion criteria. Among these,
 (3.9%) premature infants and 6 (10.0%) full-term infants were
xcluded because the parents abandoned the study prior to the
lood collection for the immunity analyses. Thus, data on 118
atients (64 in the premature group and 54 in the control group)
ere analyzed (Fig. 1).
Premature  infants had mean gestational age of 29.9 ± 2.2 weeks
variation: 25.6–34.4 weeks), birth weight of 1185 ± 216 g (vari-
tion: 714–1480 g), 23 (35.9%) were small for gestational age,
nd 48 (75.0%) had antenatal corticosteroids exposure. During the
eonatal period, 36 (56.3%), 17 (26.6%), 29 (45.3%), 36 (56.3%),
nd 16 (25.0%) had respiratory distress syndrome, patent ductus
rteriosus, clinical sepsis, intraventricular hemorrhage, retinopa-
hy of prematurity, respectively. Also, during the neonatal period,
0 (62.5%) neonates were submitted to mechanical ventilation on
edian for 6 days (variation: 1–57 days), 25 (39.1%) were on need
f oxygen therapy at 28 day of life, 6 (9.4%) received corticosteroids
uring hospitalization in the neonatal unit, 31 (48.4%) received at
east one red blood cells transfusion, 2 (3.1%) received plasma and
 (6.3%) received at least one platelet transfusion.
Table 1 summarizes the differences between the premature and
ull-term infants.
At  the beginning of the study, the premature infants had
ower weight (8119 ± 1122 g vs. 9743 ± 1100 g; p < 0.001), stature
69.9 ± 3.4 cm vs. 75.0 ± 2.8 cm,  p < 0.001) and body mass index
BMI) (16.5 ± 1.5 vs. 17.3 ± 1.3; p = 0.005), in comparison to the full-
erm infants. Four premature infants (6.3%) had a BMI  below the
2 z-score and 22 (34.3%) premature infants had a stature/age z-
core < −2, whereas all full-term infants were within the normal
ange for these indices.
Regarding  clinical evolution following discharge from the
eonatal unit, 18 (28.1%) premature infants developed pneumonia,
1 (64.1%) exhibited wheezing and 24 (37.5%) required pred-
isolone, 5.7 ± 4.5 months before booster dose at 15 months, at
 dose of 1 mg/kg/day for ﬁve days. Moreover, 24 (37.5%) required
ospitalization, with a median value of 1 (range: 1–12) hospitaliza-
ion per premature infant hospitalized. Only one child in the control
roup developed pneumonia and required hospitalization.
Mother’s milk was administered to 37 (57.8%) premature infants
nd 48 (88.9%) full-term infants (p < 0.001). Breastfeeding con-
inued for more than six months among 9 (14.1%) premature
nfants and 32 (59.3%) full-term infants (p < 0.001) and for more
han one year among 0 (0%) premature infants and 15 (27.8%)
ull-term infants (p < 0.001). Mean duration of breastfeeding was
horter among the premature infants (3.2 ± 3.7 months vs. 9.1 ± 6.3
onths; p < 0.001).
Premature infants were older at the time of the ﬁrst dose (mean
ge, 2.4 ± 0.8 months vs. 2.1 ± 0.2 months; p = 0.002), second dose
4.6 ± 0.9 months vs. 4.2 ± 0.3 months; p = 0.001) and third dose
6.9 ± 1.2 months vs. 6.2 ± 0.4 months; p < 0.001) of the tetanus
accine in comparison to the full-term infants.
The tetanus booster dose was administered at a mean age of
5.2 ± 0.3 months.
The percentage of infants with optimal protective humoral
mmunity was similar in both groups prior to and following vacci-
ation (Table 2). Among infants with minimal humoral immunity 30 (2012) 6521– 6526 6523
for  tetanus at 15 months, a greater percentage of them had been
breastfed for less than six months (37% vs. 17%; p = 0.026). Geo-
metric mean of the anti-tetanus antibody levels was lower in
the premature infants at 15 months (0.147 ± 0.2 vs. 0.205 ± 0.3;
p = 0.025) and similar in both groups at 18 months (1.997 ± 2.2 vs.
1.867 ± 2.5; p = 0.852).
Regarding cellular immunity, the percentages of CD4+ T and
CD8+ T cells expressing intracellular interferon-gamma were sim-
ilar in both groups at pre-booster and 3 months post-booster
(Table 3).
Multiple linear regression and multiple logistic regression
analyses were performed to determine an association between
demographic/clinical factors and humoral immune response to
anti-tetanus vaccination. The following independent variables
were incorporated into all regression models: use of at least one
cycle of antenatal corticosteroids; gestational age <32 weeks; small
for gestational age; clinical severity score assessed by SNAPPE II;
need for erythrocyte transfusions; BMI; and breastfeeding for more
than six months. After controlling for these variables, the ﬁnal
linear regression model showed that having been born at a ges-
tational age of less than 32 weeks was  associated with a reduction
of −0.116 IU/mL (95% CI: −0.219 to −0.014; p = 0.027) in the level
of antibodies and breastfeeding for more than six months was
associated with an increase of 0.956 IU/mL (95% CI: 0.080–1.832;
p = 0.033) in the level of antibodies after booster dose. Likewise,
after controlling for the same variables, the logistic regression
revealed that breastfeeding for more than six months was asso-
ciated with a 3.455-fold (95% CI: 1.271–9.395; p = 0.015) greater
chance of having optimal protective antibody level (≥0.1 IU/mL)
against tetanus at 15 months when compared to breastfeeding for
less than six months.
4.  Discussion
In the present study, the proportion of children with minimal
protective (≥0.01–≤0.09 IU/mL) antibody levels and potentially
susceptible to tetanus was  similar between groups at 15 months
of age. However, mean anti-tetanus antibody levels were lower
among the premature infants at 15 months of age in comparison
to the full-term infants. This ﬁnding is important, as delayed vac-
cination is more common among infants born prematurely, when
compared to the general population, which may lead some of these
children to become more susceptible to tetanus [17].
Mean age at administration of the ﬁrst three doses of the tetanus
vaccine was  signiﬁcantly greater among the premature infants than
the full-term infants, but probably not enough to confer a better
immune response for premature infants [18]. Moreover, the fact
that premature infants have lower levels of maternal antibodies
than full-term infants may  be an additional factor involved in the
better humoral immune response to vaccination [19,20]. In the
same way, Baxter et al. referred that 100% and 98.3% of 121 pre-
mature infants born less than 32 weeks of gestation developed,
respectively, a minimum and optimum antibody levels after a 3
dose primary series of tetanus vaccine [21]. However, despite these
factors, the premature infants analyzed in the present study had
lower levels of antibodies. This ﬁnding suggests the inﬂuence of
premature birth and/or possible factors associated with a lower
immune response to vaccination or a faster decay in antibody lev-
els resulting from the primary vaccination in premature infants in
comparison to those born at full term [22].
It is possible that the immune response to the tetanus vaccine in
the ﬁrst six months of life was lower among the infants born pre-
maturely, especially those born with a gestational age of less than
32 weeks, in comparison to those born at full term, as described
by other authors [5]. These results are in agreement with data
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89 Pre mat ure infan ts  wer e 
in fol low up at the 
Premature Outpa tient  Clinic
69 in fants born premature ly
fulfil led in clus ion criteria 
64 infants born 
premature ly
were studied
Full-term  infan ts wer e in follo w up at 
a Pediatric  Outpa tient  Clinic and  wer e 
invited to  par ticipate  in the study
54 infants born 
at full-term 
were s tudied
20 in fants born 
premature ly




abandoned  the 
study
6 (10.0%) infan ts 
abandoned  the 
study
60 infants  born at  full -term 
fulfil led in clus ion criteria
Fig. 1. Flow diagram showing the ﬂow of the studied infants born premature and at full-term.
Table  1
Demographic and clinical characteristics of the studied infants, during the perinatal period, expressed by mean ± sd or number and percentage.
Premature (n = 64) Full-term (n = 54) p
Mother age (years) 28 ± 8 26 ± 6 0.138*
Number of gestations 2.4 ± 1.5 1.7 ± 1.0 0.001**
Number of antenatal appointments 5.5 ± 3.6 7.9 ± 1.9 <0.001**
Hypertensive syndromes 24 (37.5%) 0 (0%) <0.001***
Diabetes mellitus 5 (7.8%) 0 (0%) 0.062***
Chorioamnionitis 6 (9.4%) 0 (0%) 0.031***
Cesarean section 48 (75.0%) 31 (57.4%) 0.043****
Male 31 (48.4%) 28 (51.9%) 0.712****
1st minute Apgar 7.1 ± 1.7 8.3 ± 0.6 <0.001*
5th minute Apgar 8.6 ± 0.7 9.2 ± 0.4 <0.001*
Gestational age (weeks) 29.9 ± 2.2 39.0 ± 1.0 <0.001*
Birth weight (g) 1185 ± 216 3231 ± 269 <0.001*
Days of hospital stay 61 ± 33 3 ± 1 <0.001**
* p: t test.
** p: Mann–Whitney test.
*** p: exact Fisher test.
**** p: 2.
Table 2
Humoral immunity against tetanus: geometric mean (variation) of antibody levels before (at 15 months) and after (at 18 months) vaccination against tetanus, expressed in
IU/mL  and number and percentages of children, according to their immunity status.
n Premature n Full-term p
Pre-vaccination (IU/mL) 63 0.147 (0.015–0.969) 54 0.205 (0.012–1.080) 0.025*
Post-vaccination (IU/mL) 62 1.997 (0.280–9.959) 53 1.867 (0.164–12.506) 0.852*
>0.1 IU/mL at 15mo 63  42 (66.7%) 54 41 (75.9%) 0.271**
0.01–0.1 IU/mL at 15mo 63 21 (33.3%) 54 13 (24.1%) 0.271**
>0.1 IU/mL at 18mo 62 62 (100%) 53 53 (100%)
mo:  months; *p: Mann–Whitney test; **p: 2. Missing data occurred due to difﬁcult venous access in three preterm infants. Parents of one term infant abandoned the study
after the ﬁrst blood collection at 15 months.
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Table 3
Percentages of CD4+ T and CD8+ T cells expressing intracellular interferon-gamma after in vitro stimulation with tetanus toxoid before (at 15 months) and after vaccination
(at 18 months).
n Premature n Full term p*
CD4+ T cells-15mo 53 2.10 ± 8.89 54 1.01 ± 3.18 0.514
CD8+  T cells-15mo 53 2.66 ± 9.66 54 2.06 ± 6.02 0.254
CD4+  T cells-18mo 54 1.55 ± 6.02 52 0.75 ± 3.36 0.686



















































bFN-: interferon-gamma; mo:  months. Missing data occurred due to difﬁculty ve
ssessment of humoral immune responses. Parents of one term infant abandoned t
* p: Mann–Whitney.
escribed in the literature stating that immune response in pre-
ature infants may  be lower in the ﬁrst six months of life due to
he lower number of circulating T and B lymphocytes and T helper
ells as well as the lower CD4/CD8 ratio in comparison to children
aving been born at full term [23].
In the present study, the premature group was recruited among
hildren born prematurely with a birth weight of less than 1500 g
nd the control group was composed of children born at full term,
dequate for gestational age, with no clinical complications in the
eonatal period and discharged from hospital by four days of life.
oreover, the control group had children within the ideal weight
ange and a good breastfeeding index until six months of age,
hereas 77% of the premature group had been born at a gestational
ge of less than 32 weeks, had a high rate of hospitalization follow-
ng discharge from the neonatal unit and a low breastfeeding index.
onetheless, the humoral response to the tetanus booster was  sim-
lar between groups and cell immunity was similar between groups
t 15 and 18 months of age. These ﬁndings show that the two
roups had a similar good memory response after a booster dose
t 15 months after having received a 3 dose primary series vaccine
gainst tetanus.
Vermeulen et al. compared 48 premature infants who  were
orn at less than 31 weeks of gestational age after vaccination
t 2, 3, and 4 months of chronological age with an acellular or
 whole-cell tetravalent diphtheria–tetanus–pertussis–polio vac-
ine. While assessing cellular immune response, the authors found
hat most of the preterm infants developed a gamma interferon
IFN-) response to the Bordetella pertussis antigens. This ﬁnding
uggests that most preterm infants are able to mount a speciﬁc
ellular immune response [24].
In the present study, the time of immune evaluation, three
onths after the booster dose, could be stated as a limitation.
t is possible that the antibody titers and numbers of circulat-
ng tetanus-speciﬁc T cells may  have decayed from peak levels
hree months after vaccination. Antibody levels following a booster
ose usually peak after 15 and 30 days. The antigen-speciﬁc
FN-producing cells most probably are found among circulating
eripheral blood mononuclear cells 1–2 weeks after vaccination
ery transiently, thereafter, they rapidly reach the lymph nodes
nd then decay with time [24–27].
With the increase in the survival rate of premature infants at
rogressively younger gestational ages and the growing use of ther-
peutic resources, premature infants currently exhibit different
haracteristics from those of past decades [28,29] and factors other
han prematurity itself may  be involved in the immune response.
hus, apart from the direct comparison of antibody levels between
roups, linear and logistic regression analyses were performed to
ontrol for variables that may  affect the response to vaccination. It
hould be pointed out that the same independent variables were
ncorporated into all multiple linear and logistic regression models,
hich contributes to the consistency of the ﬁndings.
Breastfeeding for more than six months was associated with a
.5 fold increase in the chance of having optimal protective anti-
ody levels against tetanus at 15 months of age, and a 0.96 IU/mLaccess that led to blood clotting or a small blood volume which allowed only the
dy after the ﬁrst blood collection at 15 months.
(95%  CI: 0.08–1.83) increase of antibody levels 3 months after the
booster dose. However, given the signiﬁcantly lower rates of breast-
feeding in premature infants, the effect observed of breastfeeding
could be a confounding of other factors (e.g. gestational age, afﬁnity
maturation, etc.) that could inﬂuence the antibody response levels
in these infants. However, this effect has also been described by
Greenberg et al. [30], who  found high levels of antibodies among
children who  received a conjugated vaccine against H. inﬂuenzae
type b and tetanus toxoid and had been breastfed until at least
six months of age. Jeppesen et al. [31] found a correlation between
breastfeeding and the population of T CD8+ cells. It is suggested that
breastfeeding contributes to the structural and functional develop-
ment of the thymus and the control of the apoptosis of immature
thymocytes, which subsequently transform into CD4+ T and CD8+
T cells [32].
The  use of antenatal corticosteroids, nutritional status and
erythrocyte transfusions were not associated with the humoral
response to the tetanus vaccine at 15 and 18 months, which is in
agreement with ﬁndings described in previous studies [5,8–10,33].
In conclusion, the levels of anti-tetanus antibodies were lower
among the premature infants at 15 months (pre-booster) when
compared to children born at full term, although the percentage
of children with optimal protective antibody level against tetanus
was similar in both groups. At 18 months, the premature and full-
term infants had similar humoral and cellular immune responses
to the tetanus booster vaccine. Moreover, breastfeeding increased
the odds of optimal protective antibody level against tetanus at
15 months of age and raised levels of antibodies concentration
following the tetanus booster vaccine.
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